G1 Therapeutics jumps 16.9% when trilacyclib gains FDA approval Fetching Alpha
FDA approves G1 Therapeutics’ COSELA ™ (trilacyclib): the first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression Yahoo Finance
FDA approves trilacyclib for CPPC patients undergoing chemotherapy Cancer Network
FDA approves trilacyclib to reduce chemo-induced bone marrow suppression in ES-SCLC OncLive
FDA approves G1 Therapeutics’ COSELA ™ (trilacyclib): the first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression GlobeNewswire